Article
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.
Oncotarget - 13 Sept 2016
Tarpgaard Line S, Ørum-Madsen Maj Sofie, Christensen Ib J, Nordgaard Cathrine, Noer Julie, Guren Tormod K, Glimelius Bengt, Sorbye Halfdan, Ikdahl Tone, Kure Elin H, Tveit Kjell M, Nielsen Hans J, Pfeiffer Per, Brünner Nils, Moreira José M A
Abstract excerpt
It is now widely accepted that therapeutic antibodies targeting epidermal growth factor receptor (EGFR) can have efficacy in KRAS wild-type advanced colorectal cancer (CRC) patients. What remains to be ascertained is whether a subgroup of KRAS-mutated CRC patients might not also derive benefit from EGFR inhibitors. Metalloproteinase inhibitor 1 (TIMP-1) is a pleiotropic factor predictive of survival outcome of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.